RESULTS OF FIRST-LINE TREATMENT WITH AFATINIB IN ELDERLY PATIENTS WITH STAGE IV NON-SMALL CELL LUNG CANCER WITH EGFR GENE MUTATION AT K HOSPITAL
Main Article Content
Abstract
Objective: To evaluate the results of first-line treatment of elderly patients with stage IV non-small cell lung cancer (NSCLC) with EGFR mutations using Afatinib at K Hospital from March 2018 to June 2024. Subjects and methods: Cross-sectional descriptive study of 78 patients aged 65 years and older with stage IV NSCLC with EGFR mutations, treated with Afatinib as first-line treatment at K Hospital from March 2018 to June 2024. Results: Response rate was 71.9%, disease control rate was 91.1%. Median PFS was 17.9 months, median OS was 21.0 months. PFS and OS benefits were independent of age group, gender, and gene mutation type. The prognostic factor for median OS was PS 0-1. Conclusion: First-line treatment with Afatinib in elderly patients with stage IV non-small cell lung cancer with EGFR mutations resulted in high overall response rates, disease control rates, and prolonged progression-free survival and overall survival.
Article Details
Keywords
Non-small cell lung cancer, EGFR, Afatinib, first-line treatment, elderly patients.
References

2. Zhang YL, Yuan JQ, Wang KF et al (2016) The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis. Oncotarget 7: 78985-78993.

3. Nakano Takayuki, Tanimura Keiko, Uchino Junji et al (2018) Advanced non- small cell lung cancer in elderly patients: Patients features and therapeutic management. BioMed Research International, Article ID 8202971, 8 pages, doi.org/10.1155/ 2018/820971.


4. Blanco R, Maestu I, de la Torre MG et al (2015) A review of the management of elderly patients with non-small cell lung cancer. Annal of Oncology 26: 451-463.5

5. Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016; 17(5): 577-589. doi: 10.1016/S1470-2045 (16)30033-X6.


6. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX- Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2): 213-222. doi:10.1016/ S1470-2045(13)70604-17.


7. Hung LJ, Hsu PC, Yang CT, et al. Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non- small-cell lung cancer: a multi-institute retrospective study. Aging (Albany NY). 2024; 16(1):550-567. doi:10.18632/aging.205395


8. Nguyễn Thị Thúy Hằng, Đỗ Anh Tú, Nguyễn Thị Thái Hòa và cs. Kết quả điều trị afatinib liều linh hoạt ở bệnh nhân cao tuổi UTPKTBN có đột biến EGFR. Tạp chí Y học Việt Nam. 2024;537 (1B) 136-141.

9. Nguyễn Minh Hải, Phạm Văn Luận và cs. Kết quả điều trị bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn tiến xa có đột biến gen EGFR bằng afatinib. Tạp chí Y Dược Lâm Sàng 108. 2022;17(số đặc biệt tháng 11/2022) 168-177.
